Document is current
Any future updates will be listed below
-
Authors
Perusini, Maria Agustina https://orcid.org/0000-0003-1893-6096
Andrews, Claire
Eshetu, Atenafu G. https://orcid.org/0000-0002-4613-3680
Gupta, Vikas https://orcid.org/0000-0002-1419-8607
Maze, Dawn https://orcid.org/0000-0002-4598-9380
Yee, Karen W. L. https://orcid.org/0000-0002-2572-9952
Bankar, Aniket
Davidson, Marta B.
Richard-Carpentier, Guillaume https://orcid.org/0000-0001-6452-8814
Chan, Steven M. https://orcid.org/0000-0002-4354-0731
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
Sibai, Jad
Alharbi, Salman https://orcid.org/0000-0002-3150-9876
Lucero, Josephine A.
Linn, Swe Mar
Minden, Mark D.
Schuh, Andre C.
Sibai, Hassan
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
Novartis Pharmaceuticals Corporation
Jazz Pharmaceuticals
Otsuka America Pharmaceutical
ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada
- License Information
-
More Information
Article History
Received: 16 February 2024
Revised: 19 February 2024
Accepted: 21 February 2024
First Online: 2 March 2024
Competing interests
: This study has not been funded by any pharmaceutical companies. There were no direct COI specifically related to this research project. ADS has received research funding from Takeda Pharmaceuticals, BMS, and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.
